Zebo Jiang

2.4k total citations · 1 hit paper
52 papers, 1.5k citations indexed

About

Zebo Jiang is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Zebo Jiang has authored 52 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 16 papers in Immunology and 12 papers in Oncology. Recurrent topics in Zebo Jiang's work include interferon and immune responses (7 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Immune cells in cancer (6 papers). Zebo Jiang is often cited by papers focused on interferon and immune responses (7 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Immune cells in cancer (6 papers). Zebo Jiang collaborates with scholars based in China, Macao and United States. Zebo Jiang's co-authors include Elaine Lai‐Han Leung, Xing‐Xing Fan, Jumin Huang, Xiaojun Yao, Chun Xie, Qibiao Wu, Ya‐Jia Xie, Wenjun Wang, Liang Liu and Peiyu Yan and has published in prestigious journals such as Nature Communications, PLoS ONE and Scientific Reports.

In The Last Decade

Zebo Jiang

45 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer

2021 177 citations Zebo Jiang, Wenjun Wang et al. Cancer Letters profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zebo Jiang China	23	771	341	272	236	216	52	1.5k
Parham Jabbarzadeh Kaboli China	24	857 1.1×	415 1.2×	431 1.6×	210 0.9×	189 0.9×	43	1.5k
Hanyong Chen United States	29	1.2k 1.6×	411 1.2×	270 1.0×	158 0.7×	165 0.8×	76	2.1k
Xiaojun Yao China	26	900 1.2×	308 0.9×	223 0.8×	113 0.5×	192 0.9×	85	1.7k
Mengqiu Song China	16	799 1.0×	263 0.8×	231 0.8×	127 0.5×	131 0.6×	38	1.3k
Jaemoo Chun South Korea	22	1.1k 1.4×	273 0.8×	454 1.7×	148 0.6×	153 0.7×	48	1.8k
Kai‐Yuan Lin Taiwan	30	1.2k 1.5×	297 0.9×	431 1.6×	104 0.4×	276 1.3×	75	2.0k
Bum Sang Shim South Korea	26	1.1k 1.4×	383 1.1×	262 1.0×	141 0.6×	105 0.5×	62	1.9k
Addanki P. Kumar United States	27	1.0k 1.4×	561 1.6×	436 1.6×	140 0.6×	274 1.3×	56	1.9k
Do Young Lim United States	25	1.0k 1.3×	334 1.0×	214 0.8×	287 1.2×	79 0.4×	44	1.9k
Antonella D’Anneo Italy	29	1.3k 1.7×	362 1.1×	443 1.6×	130 0.6×	117 0.5×	74	2.2k

Countries citing papers authored by Zebo Jiang

Since Specialization

Citations

This map shows the geographic impact of Zebo Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zebo Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zebo Jiang more than expected).

Fields of papers citing papers by Zebo Jiang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zebo Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zebo Jiang. The network helps show where Zebo Jiang may publish in the future.

Co-authorship network of co-authors of Zebo Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Zebo Jiang. A scholar is included among the top collaborators of Zebo Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zebo Jiang. Zebo Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kang, Liping, H. Y. Huang, Pan Xu, et al.. (2025). Pterostilbene inhibits non-small cell lung cancer progression by activating the STING pathway and enhancing antitumor immune response. Frontiers in Immunology. 16. 1622284–1622284.

Ni, Feng, Huixian Wang, Jie Hu, et al.. (2025). Pyroptosis-driven immune dysregulation in COPD: molecular mechanisms and therapeutic implications. Frontiers in Immunology. 16. 1686175–1686175.

Jiang, Zebo, Qiang He, Liping Kang, et al.. (2025). Rutecarpine Suppresses Non‐Small Cell Lung Cancer Progression Through Activating the STING Pathway and Elevating CD8+ T Cells. Chemical Biology & Drug Design. 105(2). e70070–e70070.

Yu, Hailing, Yin Huang, Ting Yu, et al.. (2025). Engineering biocompatible carbon dots nano-enzymes hydrogel for efficient antioxidative and anti-inflammatory treatment of dry eye disease. Journal of Controlled Release. 381. 113490–113490. 5 indexed citations

Li, Xi, Yan Zhi Tan, Zebo Jiang, et al.. (2024). STING agonist-based hydrogel enhances immune activation in synergy with radiofrequency ablation for hepatocellular carcinoma treatment. Journal of Controlled Release. 369. 296–308. 28 indexed citations

Tan, Yan Zhi, et al.. (2024). Tetrandrine activates STING/TBK1/IRF3 pathway to potentiate anti-PD-1 immunotherapy efficacy in non-small cell lung cancer. Pharmacological Research. 207. 107314–107314. 13 indexed citations

Yang, Fan, Zebo Jiang, Mengzhu Li, et al.. (2023). pH-sensitive molybdenum (Mo)-based polyoxometalate nanoclusters have therapeutic efficacy in inflammatory bowel disease by counteracting ferroptosis. Pharmacological Research. 188. 106645–106645. 36 indexed citations

Liu, Chunping, Huiqi Chen, Zhijun Chen, et al.. (2023). Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions. Biomedicine & Pharmacotherapy. 166. 115373–115373. 14 indexed citations

Liu, Chunping, Yanjiao Liu, Haiding Huang, et al.. (2022). Immunity: Psoriasis comorbid with atherosclerosis. Frontiers in Immunology. 13. 1070750–1070750. 11 indexed citations

10.

Huang, Min, Dan Li, Ya‐Jia Xie, et al.. (2022). PA-MSHA induces inflamed tumor microenvironment and sensitizes tumor to anti-PD-1 therapy. Cell Death and Disease. 13(11). 931–931. 6 indexed citations

11.

Xu, Duo, Fan Yang, Fen Wang, et al.. (2022). Novel STING-targeted PET radiotracer for alert and therapeutic evaluation of acute lung injury. Acta Pharmaceutica Sinica B. 13(5). 2124–2137. 15 indexed citations

12.

Wang, Xuan‐Run, Zebo Jiang, Cong Xu, et al.. (2022). Andrographolide suppresses non-small-cell lung cancer progression through induction of autophagy and antitumor immune response. Pharmacological Research. 179. 106198–106198. 54 indexed citations

13.

Jiang, Zebo, Wenjun Wang, Cong Xu, et al.. (2021). Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer. Cancer Letters. 515. 36–48. 177 indexed citations breakdown →

14.

Li, Jiaxin, Runze Li, Ao Sun, et al.. (2021). Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing decoction by suppression of PRKCA and sphingolipid signaling. Pharmacological Research. 171. 105574–105574. 67 indexed citations

15.

Huang, Jumin, Zebo Jiang, Yuwei Wang, et al.. (2020). Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy. Current Opinion in Pharmacology. 54. 1–10. 45 indexed citations

16.

Jiang, Zebo, Jumin Huang, Ya‐Jia Xie, et al.. (2020). Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis. Journal of Experimental & Clinical Cancer Research. 39(1). 249–249. 93 indexed citations

17.

Wang, Wenjun, Huanling Lai, Yuwei Wang, et al.. (2020). Dolutegravir derivative inhibits proliferation and induces apoptosis of non-small cell lung cancer cells via calcium signaling pathway. Pharmacological Research. 161. 105129–105129. 30 indexed citations

18.

Li, Runze, Zebo Jiang, Chunli Wei, et al.. (2018). Honokiol Inhibits Proliferation, Invasion and Induces Apoptosis Through Targeting Lyn Kinase in Human Lung Adenocarcinoma Cells. Frontiers in Pharmacology. 9. 558–558. 16 indexed citations

19.

Huang, Run-Yue, et al.. (2014). Glycyrrhizin Suppresses Lung Adenocarcinoma Cell Growth Through Inhibition of Thromboxane Synthase. Cellular Physiology and Biochemistry. 33(2). 375–388. 56 indexed citations

20.

Huang, Run-Yue, Yong‐Liang Chu, Qingchun Huang, et al.. (2014). 18β-Glycyrrhetinic Acid Suppresses Cell Proliferation through Inhibiting Thromboxane Synthase in Non-Small Cell Lung Cancer. PLoS ONE. 9(4). e93690–e93690. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact